Lumiradx reports fourth quarter and full year 2021 results

London, march 10, 2022 /prnewswire/ -- lumiradx limited (nasdaq:lmdx), a next-generation point of care (poc) diagnostics company, today announced financial and operational results for the fourth quarter and full year ended december 31, 2021. full year 2021 revenues of $421.4 million up from full year 2020 revenue of $139.2 million, as the pandemic accelerated momentum on our long-term growth strategy fourth quarter 2021 revenue of $118.3 million rose sequentially compared to strong third quarter 2021 revenue of $109.1 million and year over year versus fourth quarter 2020 revenue of $112.3 million customer use of our platform to support several tests including sars-cov-2antigen, d-dimer for diagnosing thrombotic conditions and crp for antibiotic stewardship being credited for streamlining treatment and reducing cost and stress on health systems customer instrument shipments total more than 21,000 platforms as of december 31, 2021 strong start to the year with an estimated 4,000 instruments to be shipped for the first quarter of 2022 and first quarter 2022 revenues expected to be similar to fourth quarter 2021 "lumiradx's strong 2021 performance marks an inflection point in our strategy for transforming community-based diagnostics," said ron zwanziger, chairman and ceo of lumiradx.
LMDX Ratings Summary
LMDX Quant Ranking